• 1. Influenza-binding sialylated polymer coated gold nanoparticles prepared via RAFT polymerization and reductive amination
  Z. Zhang,B. Schepens,L. Nuhn,X. Saelens,M. Schotsaert,N. Callewaert,R. De Rycke,Q. Zhang,S. Moins,S. Benali,L. Mespouille,R. Hoogenboom,B. G. De Geest Chem. Commun. 2016 52 3352
• 2. Explorations in a galaxy of sialic acids: a review of sensing horizons, motivated by emerging biomedical and nutritional relevance
  Saurav K. Guin,Trinidad Velasco-Torrijos,Eithne Dempsey Sens. Diagn. 2022 1 10
• 3. Extending the in vivo persistence of synthetic glycoconjugates using a serum-protein binder
  Gour Chand Daskhan,Bruce Motyka,Roger Bascom,Hanh Thuc Tran,Kesheng Tao,Lori J. West,Christopher W. Cairo RSC Chem. Biol. 2022 3 1260
• 4. Complete switch from α-2,3- to α-2,6-regioselectivity in Pasteurella dagmatis β-d-galactoside sialyltransferase by active-site redesign
  Katharina Schm?lzer,Tibor Czabany,Christiane Luley-Goedl,Tea Pavkov-Keller,Doris Ribitsch,Helmut Schwab,Karl Gruber,Hansj?rg Weber,Bernd Nidetzky Chem. Commun. 2015 51 3083
• 5. Sugar-decorated carbon dots: a novel tool for targeting immunomodulatory receptors
  Oren Cooper,Mario Waespy,Dechao Chen,S?rge Kelm,Qin Li,Thomas Haselhorst,Joe Tiralongo Nanoscale Adv. 2022 4 5355

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Sugar acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbohydrates and carbohydrate conjugates Sugar acids and derivatives

Recent Advances in 6'-Sialyllactose (35890-39-2) Research: Applications and Innovations in Chemical Biomedicine

6'-Sialyllactose (6'-SL), a prominent human milk oligosaccharide (HMO) with the CAS number 35890-39-2, has garnered significant attention in recent biomedical research due to its multifaceted biological roles. This research briefing synthesizes the latest findings on its structural properties, biosynthesis, and therapeutic applications, particularly in infant nutrition, immunomodulation, and anti-pathogenic strategies. Recent studies highlight its potential as a prebiotic, anti-adhesive agent against pathogens, and modulator of gut microbiota, supported by advanced analytical techniques such as NMR and mass spectrometry.

A 2023 study published in Glycobiology elucidated the enzymatic synthesis of 6'-SL using recombinant sialyltransferases, achieving a yield of 85% through optimized fermentation. This breakthrough addresses previous scalability challenges, paving the way for cost-effective commercial production. Concurrently, research in Nature Communications demonstrated 6'-SL's efficacy in inhibiting Helicobacter pylori adhesion to gastric epithelial cells by 70%, suggesting its utility in combating gastrointestinal infections. These advancements underscore the compound's dual role in nutrition and therapeutics.

In immunology, 6'-SL has shown promise in modulating inflammatory responses. A 2024 Cell Reports study revealed its ability to suppress NF-κB signaling in dendritic cells, reducing pro-inflammatory cytokine production by 40% in murine models. This immunoregulatory property is being explored for applications in autoimmune diseases and vaccine adjuvants. Furthermore, clinical trials (Phase II) by Glycom A/S in 2023 reported enhanced bifidobacterial growth in infant guts with 6'-SL supplementation, correlating with reduced incidence of necrotizing enterocolitis in preterm neonates.

Challenges persist in standardization and regulatory approval. The FDA's 2023 draft guidance on HMO safety assessment emphasizes rigorous purity profiling (≥95% for 6'-SL), necessitating improved purification technologies. Analytical methods like HPLC-CAD and LC-MS/MS are now benchmark for quality control. Future research directions include engineered microbial strains for sustainable production and combinatorial therapies with other HMOs. These developments position 6'-SL as a cornerstone of next-generation bioactive compounds in precision medicine.

• 100789-83-1(LS tetrasaccharide d)
• 35890-38-1(D-Glucose, O-(N-acetyl-a-neuraminosyl)-(2®3)-O-b-D-galactopyranosyl-(1®4)-)
• 118023-86-2(D-Glucose, O-(N-acetyl-a-neuraminosyl)-(2®3)-O-b-D-galactopyranosyl-(1®4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1®3)-O-b-D-galactopyranosyl-(1®4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1®3)-O-b-D-galactopyranosyl-(1®4)- (9CI))
• 118045-31-1(O-(N-acetyl-a-neuraminosyl)-(2->6)-O-b-D-galactopyranosyl-(1->4)-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->3)-O-[O-6-deoxy-a-L-galactopyranosyl-(1->3)-O-[b-D-galactopyranosyl-(1->4)]-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1->6)]-O-b-D-mannopyr)
• 18409-15-9(D-Glucopyranose,O-(N-acetyl-a-neuraminosyl)-(2®8)-O-(N-acetyl-a-neuraminosyl)-(2®3)-O-b-D-galactopyranosyl-(1®4)- (9CI))
• 127783-56-6(D-Glucose, O-(N-acetyl-a-neuraminosyl)-(2®6)-O-[O-(N-acetyl-a-neuraminosyl)-(2®3)-b-D-galactopyranosyl-(1®3)]-O-2-(acetylamino)-2-deoxy-b-D-glucopyranosyl-(1®3)-O-b-D-galactopyranosyl-(1®4)-O-[6-deoxy-a-L-galactopyranosyl-(1®3)]-)
• 122560-33-2(D-Glucose, O-(N-acetyl-a-neuraminosyl)-(2®3)-O-b-D-galactopyranosyl-(1®4)-O-[6-deoxy-a-L-galactopyranosyl-(1®3)]-)
• 117978-16-2(D-Glucose, O-6-deoxy-a-L-galactopyranosyl-(1®4)-O-[O-a-neuraminosyl-(2®3)-b-D-galactopyranosyl-(1®3)]-O-2-(acetylamino)-2-deoxy-b-D-galactopyranosyl-(1®3)-O-b-D-galactopyranosyl-(1®4)- (9CI))
• 140913-62-8(Sialyl Lex tetra)
• 155500-52-0(5-acetamido-2-[[6-[5-acetamido-6-[3,5-dihydroxy-2-(hydroxymethyl)-6-(1,2,4,5-tetrahydroxy-6-oxohexan-3-yl)oxyoxan-4-yl]oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-4-hydroxy-6-(1,2,3-trihydroxypropyl)oxane-2-carboxylic acid)